Trial reportSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2014
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
Trial report in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00311246 (A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis.Thorax · 2025Pooled it
- Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.Frontiers in medicine · 2022Pooled it
- Sarcoidosis: A Clinical Trials Perspective.Pulmonary therapy · 2026Review
- Positron Emission Tomography imaging of tumor necrosis factor in lung injury.Upsala journal of medical sciences · 2026Article
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history.Dermatology reports · 2025Article
- Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.Journal of clinical medicine · 2025Review
- Fibrotic Pulmonary Sarcoidosis-From Pathogenesis to Management.Journal of clinical medicine · 2025Review
- Latent microbial reactivation and immune dysregulation in sarcoidosis: bridging pathogenesis and precision therapeutics.Frontiers in medicine · 2025Review
- A review of sarcoidosis etiology, diagnosis and treatment.Frontiers in medicine · 2025Review
- [Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024].Wiener klinische Wochenschrift · 2024Article
- Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions.Cureus · 2024Review
- Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis.Journal of clinical medicine · 2024Review
- Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.Journal of clinical medicine · 2023Review
- The Symptoms of Pulmonary Sarcoidosis.Journal of clinical medicine · 2023Review
- Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.JID innovations : skin science from molecules to population health · 2023Review
- Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease.Frontiers in cell and developmental biology · 2023Review
- Assessment of treatment response in cardiac sarcoidosis based on myocardialFrontiers in immunology · 2023Article
- Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives.Frontiers in immunology · 2023Review
- Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review.Respiratory medicine case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundInfliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis.
methodsAn open-label, single-center study was conducted in 11 patients with refractory pulmonary sarcoidosis. Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52. The primary endpoint was the percent change in predicted forced vital capacity (FVC) at 24 weeks. Secondary efficacy parameters included the 6-minute walk test (6MWT), Borg dyspnea score, and Physician's (PGA) and Patient's (PaGA) Global Assessments. A successful outcome of the study was defined as reduction in immunosuppressive therapy (prednisone to 10 mg or less), improvement in FVC of 5% or greater, improvement in 6-minute walk test distance (6MWD) of 50 meter or greater at the end of weeks 24 and 52.
resultsEleven patients received adalimumab and had 24-week follow-ups. Only ten patients had a Week 52 evaluation. FVC stabilized in seven patients, and four patients showed improvement in FVC. Five patients had improved 6MWD, and nine had lower Borg dyspnea scores. PGA and PaGA improved at weeks 24 and 52 for all patients (P<0.008 for all comparisons). Among 11 patients who underwent adalimumab treatment, 9 (82%) and 8(80%) had a successful outcome at the end of 24 and 52 weeks respectively. No severe adverse incidents were reported.
conclusionsIn this small, open-label study, adalimumab improved refractory pulmonary sarcoidosis and was well tolerated (ClinicalTrials.gov identifier NCT00311246).
Indexed as
Identifiers
24751453PMC4134103W1522561918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.